# Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma

> **NCT05058755** · NA · COMPLETED · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 62 (actual)

## Conditions studied

- Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type

## Interventions

- **DRUG:** tislelizumab, azacytidine, lenalidomide
- **DRUG:** tislelizumab, etoposide, pegaspargase

## Key facts

- **NCT ID:** NCT05058755
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-17
- **Primary completion:** 2022-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05058755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05058755, "Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05058755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*